Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection

Abstract

Terumo BCT recently introduced a new system for mononuclear cell (MNC) collection that uses a Spectra Optia apheresis machine equipped with a redesigned disposable kit and software program (version 11.2). It allows for the continuous collection of MNCs, unlike the original Spectra Optia system (version 7.2), which included a chamber for two-step cell separation. The aim of this study was to compare the two apheresis systems in regard to specific performance parameters. A retrospective data analysis of 150 patients who had undergone peripheral blood stem cell collection between March of 2014 and May of 2015 at our institution was performed. For the matched comparison, patients were divided into two groups by diagnosis and by previous forms of therapy received: a homogeneous group of patients with multiple myeloma (MM) that had received first line therapy ("MM" group, n = 88) and a heterogeneous group that included all of the other patients ("other" group, n = 62). No significant differences in CD34+ collection yields between both collection regimens were found (p = 0.19, p = 0.74) in either group. Moreover, similar performance ratios (collected/predicted CD34+ cell number in %) were observed (p = 0.89, p = 0.1). No relevant variations in platelet or hemoglobin loss were found between the two systems. We conclude that the new continuous Spectra Optia MNC system is equally efficient in collecting CD34+ cells and can be used without sacrificing collection efficiency levels when treating a broad variety of autologous patients. J. Clin. Apheresis 32:27-34, 2017. © 2016 Wiley Periodicals, Inc.

Therapeutic white blood cell and platelet depletions using the spectra OPTIA system continuous mononuclear cell protocol

“…Our results are consistent with findings in the literature that have demonstrated equivalent therapeutic depletion results between the COBE Spectra and the Spectra Optia; Additionally, we found no significant difference in outcome parameters between the 2 apheresis systems. These findings are consistent with the published literature, which shows that hematocrit and platelet counts exhibit a periprocedural decline that is consistent across apheresis systems and leukapheresis protocols …”

Performance prediction algorithm for autologous PBSC collection in adults and pediatric patients using large volume leukapheresis

“…Here we assessed the processing of larger blood volumes using the new continuous mononuclear cell collection (CMNC) protocol on the Spectra Optia apheresis system (Terumo BCT, USA). While the feasibility and efficiency of stem cell collection using Spectra Optia CMNC has been reported previously, this is the first study on LVL performance in pediatric patients assessing side effects, anticoagulant choice and specialized procedures such as adequate venous access and extracorporeal volume . In addition, CD34+ cell yield predictability, determined using a customized algorithm to estimate the blood processing volume required based on circulating CD34+ count and linear regression variables, was assessed.…”

Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result

“…Stem cells were collected via peripheral or central venous catheters using a Spectra Optia ® apheresis machine (software V7.2 and two-step tubing system or software V11.2 and cMNC (continuous mononuclear cell collection) tubing system) according to the manufacturers' instructions (TerumoBCT, Zaventem, Belgium) and default settings as described previously [22]. The maximum total blood volume processed was four times the patient's blood volume without an absolute limit.…”